Placebo booster

BIOLOGICAL2 trials

Sponsors

Arcturus Therapeutics, Inc., Bavarian Nordic

Conditions

Chikungunya Virus InfectionCorona Virus InfectionCovid19SARS-CoV Infection

Phase 2

A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

TerminatedNCT04668339

Arcturus Therapeutics, Inc.Corona Virus Infection, Covid19, SARS-CoV Infection

Start: 2021-01-07End: 2022-03-01Updated: 2025-05-15

Phase 3

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination

Active, not recruitingNCT06007183

Bavarian NordicChikungunya Virus Infection

Start: 2023-08-30End: 2028-02-01Updated: 2026-08-07

Related Papers

Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials.

2024-05-1457 citations